

THERMOGENESIS CORP
Form 8-K
December 04, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

November 30, 2009

ThermoGenesis Corp.

(Exact name of registrant as specified in its charter)

Delaware

333-82900

94-3018487

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

2711 Citrus Rd., Rancho Cordova, California

95742

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

916-858-5100

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 1.01 Entry into a Material Definitive Agreement.

On November 30, 2009 ThermoGenesis Corp. ("Thermo") entered into an Amendment to the Amended and Restated International Distribution Agreement Concerning the AXP Platform with GE Healthcare Bio-Sciences A.B., a GE Healthcare company ("GEHC"). Under the terms of the amendment, the parties agreed to extend the deadline for termination on renewal notification to eleven (11) months prior to the contract termination date of December 31, 2010, from the original deadline of twelve (12) months.

Item 9.01 Financial Statements and Exhibits.

10. Amendment to Amended and Restated International Distribution Agreement Concerning the AXP Platform dated November 17, 2009.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ThermoGenesis Corp.

December 3, 2009

By: *Matthew T. Plavan*

Name: Matthew T. Plavan

Title: EVP, COO & CFO

Top of the Form

Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>
10	Amendment to Amended and Restated International Distribution Agreement Concerning the AXP Platform